225 related articles for article (PubMed ID: 35058934)
41. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
42. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
43. A New Hope for CD56
Forconi CS; Oduor CI; Oluoch PO; Ong'echa JM; Münz C; Bailey JA; Moormann AM
Front Cell Infect Microbiol; 2020; 10():162. PubMed ID: 32373555
[TBL] [Abstract][Full Text] [Related]
44. CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.
Reeves RK; Gillis J; Wong FE; Yu Y; Connole M; Johnson RP
Blood; 2010 Jun; 115(22):4439-46. PubMed ID: 20339088
[TBL] [Abstract][Full Text] [Related]
45. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
Yu J; Mao HC; Wei M; Hughes T; Zhang J; Park IK; Liu S; McClory S; Marcucci G; Trotta R; Caligiuri MA
Blood; 2010 Jan; 115(2):274-81. PubMed ID: 19897577
[TBL] [Abstract][Full Text] [Related]
46. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
Ndhlovu LC; Lopez-Vergès S; Barbour JD; Jones RB; Jha AR; Long BR; Schoeffler EC; Fujita T; Nixon DF; Lanier LL
Blood; 2012 Apr; 119(16):3734-43. PubMed ID: 22383801
[TBL] [Abstract][Full Text] [Related]
47. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells.
Juelke K; Killig M; Luetke-Eversloh M; Parente E; Gruen J; Morandi B; Ferlazzo G; Thiel A; Schmitt-Knosalla I; Romagnani C
Blood; 2010 Aug; 116(8):1299-307. PubMed ID: 20505160
[TBL] [Abstract][Full Text] [Related]
48. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
49. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
50. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic.
Ferlazzo G; Thomas D; Lin SL; Goodman K; Morandi B; Muller WA; Moretta A; Münz C
J Immunol; 2004 Feb; 172(3):1455-62. PubMed ID: 14734722
[TBL] [Abstract][Full Text] [Related]
51. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
Oliviero B; Mele D; Degasperi E; Aghemo A; Cremonesi E; Rumi MG; Tinelli C; Varchetta S; Mantovani S; Colombo M; Mondelli MU
J Hepatol; 2013 Jul; 59(1):38-44. PubMed ID: 23499727
[TBL] [Abstract][Full Text] [Related]
52. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling.
Hanna J; Bechtel P; Zhai Y; Youssef F; McLachlan K; Mandelboim O
J Immunol; 2004 Dec; 173(11):6547-63. PubMed ID: 15557145
[TBL] [Abstract][Full Text] [Related]
53. The IL-12 signature: NK cell terminal CD56+high stage and effector functions.
Loza MJ; Perussia B
J Immunol; 2004 Jan; 172(1):88-96. PubMed ID: 14688313
[TBL] [Abstract][Full Text] [Related]
54. Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients.
Mahgoub S; Abosalem H; Emara M; Kotb N; Maged A; Soror S
Mol Immunol; 2021 Sep; 137():221-227. PubMed ID: 34284214
[TBL] [Abstract][Full Text] [Related]
55. Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry.
Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
BMC Immunol; 2019 May; 20(1):14. PubMed ID: 31077146
[TBL] [Abstract][Full Text] [Related]
56. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
57. Deficient IL-2 Produced by Activated CD56
Xie Z; Zheng J; Wang Y; Li D; Maermaer T; Li Y; Tu J; Xu Q; Liang H; Cai W; Shen T
Front Immunol; 2019; 10():1647. PubMed ID: 31379845
[No Abstract] [Full Text] [Related]
58. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity.
Lichtfuss GF; Meehan AC; Cheng WJ; Cameron PU; Lewin SR; Crowe SM; Jaworowski A
J Leukoc Biol; 2011 Jan; 89(1):149-58. PubMed ID: 20884651
[TBL] [Abstract][Full Text] [Related]
59. The immune potential of decidua-resident CD16
Zhang J; Lye SJ
Hum Immunol; 2021 May; 82(5):332-339. PubMed ID: 33583640
[TBL] [Abstract][Full Text] [Related]
60. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
